Sangamo Biosciences, Inc.  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
+0.15 (1.21%)
Jun 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.13 - 12.92
52 week 9.39 - 19.25
Open 12.32
Vol / Avg. 1.67M/846,152.00
Mkt cap 861.44M
P/E     -
Div/yield     -
EPS -0.35
Shares 69.58M
Beta 2.07
Inst. own 81%
Jul 21, 2015
Q2 2015 Sangamo BioSciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 22, 2015
Sangamo BioSciences Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
Jun 1, 2015
Sangamo BioSciences Inc at Jefferies Global Healthcare Conference
May 19, 2015
Sangamo BioSciences Inc at UBS Global Healthcare Conference
May 14, 2015
Sangamo BioSciences Inc at Bank of America Merrill Lynch Health Care Conference
Apr 22, 2015
Q1 2015 Sangamo BioSciences Inc Earnings Call - Webcast
Apr 22, 2015
Q1 2015 Sangamo BioSciences Inc Earnings Release
Mar 25, 2015
Sangamo BioSciences Inc at Alliance for Regenerative Medicine RegenMed Investor Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -39.43% -57.59%
Operating margin -46.11% -58.38%
EBITD margin - -57.19%
Return on average assets -8.86% -13.76%
Return on average equity -10.30% -16.09%
Employees 102 -
CDP Score - -


501 Canal Blvd
RICHMOND, CA 94804-3559
United States - Map
+1-510-9706000 (Phone)
+1-510-2368951 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sangamo Biosciences, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the research, development and commercialization of engineered DNA-binding proteins for the development of therapeutic strategies for unmet medical needs. The Company’s mission is to develop ZFP Therapeutics, which is human therapeutics based on the Company’s ZFP technology through early stage clinical testing, strategically partner with biopharmaceutical companies at points of value inflection and have the partner execute late-stage clinical trials and commercial development. The Company’s lead ZFP Therapeutic, SB-728-T, ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is a therapeutic application of ZFN technology and is being evaluated in ongoing clinical trials, a Phase 2 study and a Phase 1/2 study in HIV-infected subjects.

Officers and directors

William R Ringo Jr Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Edward O. Lanphier II President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
H. Ward Wolff Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Age: 66
Bio & Compensation  - Reuters
Geoffrey M. Nichol Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Philip D. Gregory Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 43
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 59
Bio & Compensation  - Reuters
Paul B. Cleveland Independent Director
Age: 57
Bio & Compensation  - Reuters
Stephen G. Dilly Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Larson Independent Director
Age: 75
Bio & Compensation  - Reuters